Stoke Therapeutics, Inc. (NASDAQ:STOK – Get Free Report) major shareholder Skorpios Trust sold 3,600,000 shares of the company’s stock in a transaction dated Wednesday, April 17th. The shares were sold at an average price of $11.60, for a total transaction of $41,760,000.00. Following the transaction, the insider now owns 10,843,681 shares in the company, valued at $125,786,699.60. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.
Stoke Therapeutics Stock Performance
STOK stock traded down $0.07 during mid-day trading on Thursday, hitting $11.65. 1,059,325 shares of the company were exchanged, compared to its average volume of 971,695. The firm has a market cap of $539.40 million, a P/E ratio of -5.01 and a beta of 0.77. The firm’s 50 day simple moving average is $8.47 and its 200 day simple moving average is $5.89. Stoke Therapeutics, Inc. has a 1-year low of $3.35 and a 1-year high of $16.40.
Stoke Therapeutics (NASDAQ:STOK – Get Free Report) last announced its earnings results on Monday, March 25th. The company reported ($0.60) EPS for the quarter, topping the consensus estimate of ($0.62) by $0.02. The company had revenue of $2.80 million for the quarter, compared to analyst estimates of $3.70 million. On average, equities research analysts predict that Stoke Therapeutics, Inc. will post -2.28 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Read Our Latest Stock Analysis on Stoke Therapeutics
Institutional Trading of Stoke Therapeutics
Several hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. raised its holdings in Stoke Therapeutics by 1.1% during the 4th quarter. Vanguard Group Inc. now owns 1,648,502 shares of the company’s stock worth $8,671,000 after buying an additional 17,814 shares during the period. Barclays PLC raised its holdings in Stoke Therapeutics by 365.3% during the 4th quarter. Barclays PLC now owns 39,271 shares of the company’s stock worth $206,000 after buying an additional 30,831 shares during the period. Granahan Investment Management LLC grew its stake in shares of Stoke Therapeutics by 33.7% during the 4th quarter. Granahan Investment Management LLC now owns 1,137,887 shares of the company’s stock worth $5,985,000 after acquiring an additional 286,686 shares in the last quarter. Bridgeway Capital Management LLC bought a new position in shares of Stoke Therapeutics during the 4th quarter worth approximately $90,000. Finally, Birchview Capital LP grew its stake in shares of Stoke Therapeutics by 147.1% during the 4th quarter. Birchview Capital LP now owns 210,000 shares of the company’s stock worth $1,105,000 after acquiring an additional 125,000 shares in the last quarter.
About Stoke Therapeutics
Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.
Featured Stories
- Five stocks we like better than Stoke Therapeutics
- Insider Trading – What You Need to Know
- Comprehensive PepsiCo Stock Analysis
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- CSX Co.: The Railroad Powering Ahead with an Earnings Beat
- What Does Downgrade Mean in Investing?
- Bear Market Funds to Watch This Year
Receive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.